West Pharma (WST) Tops Q2 EPS by 1c; Lowers Top End of EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
West Announces Second-Quarter 2017 Results
July 27, 2017 6:00 AM EDTEXTON, Pa., July 27, 2017 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2017 and updated financial guidance for the full-year 2017.
Second-Quarter 2017 Highlights
Reported net sales of $397.6 million, a record high, grew 2.5% over the prior-year quarter. Net sales at constant currency (organic) grew by 3.9%. Second-quarter 2017 reported-diluted EPS was $0.51, compared to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS was $0.66, compared to $0.59 in the prior-year quarter. Second-quarter 2017 reported and adjusted-diluted EPS include the impact... More